Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]
Discontinued
Reference number: GID-TA10495
As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.